<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505374</url>
  </required_header>
  <id_info>
    <org_study_id>11155</org_study_id>
    <nct_id>NCT01505374</nct_id>
  </id_info>
  <brief_title>Saphenous Nerve Block vs. Femoral Nerve Block for Total Knee Arthroplasty</brief_title>
  <official_title>Saphenous Nerve Block vs. Femoral Nerve Block for Total Knee Arthroplasty: A Comparative Effectiveness Study in Bilateral Total Knee Arthroplasty Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, the regional anesthetic standard of care for total knee replacement surgery is
      combined spinal/epidural to provide long-lasting pain relief with or without a femoral nerve
      block (FNB). The femoral nerve block refers to a technique that your anesthesiologist can use
      to numb the thigh muscle for approximately 18 hours after surgery. While this technique
      offers significant pain relief, it is possible it may cause muscle weakness and increase
      patients' recovery times. Hence there is a need for an alterative anesthetic technique, one
      that may help minimize postoperative pain as effectively as a femoral nerve block, while not
      causing weakness of the thigh muscle.

      The saphenous nerve, a branch of the femoral nerve, provides sensation to the knee. Thus it
      is hypothesized by &quot;blocking&quot; or anesthetizing the saphenous nerve with local anesthetic
      closer to where it branches off, the area around and below the knee will feel numb. Yet
      unlike the femoral nerve block, the thigh muscle itself will still be able to function.

      For patients undergoing two total knee replacements at one time or bilateral total knee
      replacement, they will be randomly assigned to receive a femoral nerve block on one leg and a
      saphenous block on the other. Pain levels will be measured and thigh muscle strength will be
      tested using a dynamometer before surgery, 6-8 hours following anesthesia administration, and
      on postoperative days 1 and 2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale Pain Score</measure>
    <time_frame>Up to postoperative day 1</time_frame>
    <description>The primary outcome is the postoperative pain in each leg within the first 24 hours postoperatively. VAS pain scores could range from 0 to 10. Higher values represent a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tracking Total Opioid Usage</measure>
    <time_frame>Up to postoperative day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative and Postoperative Thigh Muscle Strength in Both Legs</measure>
    <time_frame>Up to postoperative day 2</time_frame>
    <description>This was measured with a dynamometer to gauge strength.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Nerve Blocks</measure>
    <time_frame>Up to postoperative day 1</time_frame>
    <description>Rated on a 0-10 scale, with a higher score representing greater satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Motor and Sensory Blockade</measure>
    <time_frame>Up to postoperative day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating the Success of the Nerve Blocks</measure>
    <time_frame>Up to postoperative day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications</measure>
    <time_frame>Up to postoperative day 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Difference Between Femoral Nerve Block and Saphenous Block</condition>
  <arm_group>
    <arm_group_label>Study Technique Left Leg, Control Technique Right Leg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Technique Right Leg, Control Technique Left Leg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Study Technique</intervention_name>
    <description>One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.</description>
    <arm_group_label>Study Technique Left Leg, Control Technique Right Leg</arm_group_label>
    <arm_group_label>Study Technique Right Leg, Control Technique Left Leg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control Technique</intervention_name>
    <description>The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.</description>
    <arm_group_label>Study Technique Left Leg, Control Technique Right Leg</arm_group_label>
    <arm_group_label>Study Technique Right Leg, Control Technique Left Leg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients ages 40-80 undergoing Bilateral Total Knee Replacement

          -  Planned use of neuraxial anesthesia

          -  Ability to follow study protocol

        Exclusion Criteria:

          -  Contraindication to a spinal or epidural anesthestic

          -  Not a candidate for bilateral total knee replacement

          -  Chronic opioid use (defined as daily or almost daily use of opioids for &gt;3 months)

          -  Hypersensitivity and/or allergy to local anesthetics

          -  Intraoperative use of any volatile anesthetic

          -  Patients with pre-existing neuropathy on the operative limb

          -  Contraindication to femoral nerve block or saphenous nerve block

          -  Allergy to any of the study medications

          -  American Society of Anesthesiologists (ASA) Class 4-5

          -  Non-English speaking patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stavros G. Memtsoudis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Capdevila X, Barthelet Y, Biboulet P, Ryckwaert Y, Rubenovitch J, d'Athis F. Effects of perioperative analgesic technique on the surgical outcome and duration of rehabilitation after major knee surgery. Anesthesiology. 1999 Jul;91(1):8-15.</citation>
    <PMID>10422923</PMID>
  </reference>
  <reference>
    <citation>Singelyn FJ, Ferrant T, Malisse MF, Joris D. Effects of intravenous patient-controlled analgesia with morphine, continuous epidural analgesia, and continuous femoral nerve sheath block on rehabilitation after unilateral total-hip arthroplasty. Reg Anesth Pain Med. 2005 Sep-Oct;30(5):452-7.</citation>
    <PMID>16135349</PMID>
  </reference>
  <reference>
    <citation>Kandasami M, Kinninmonth AW, Sarungi M, Baines J, Scott NB. Femoral nerve block for total knee replacement - a word of caution. Knee. 2009 Mar;16(2):98-100. doi: 10.1016/j.knee.2008.10.007. Epub 2008 Nov 28.</citation>
    <PMID>19046884</PMID>
  </reference>
  <reference>
    <citation>Horn JL, Pitsch T, Salinas F, Benninger B. Anatomic basis to the ultrasound-guided approach for saphenous nerve blockade. Reg Anesth Pain Med. 2009 Sep-Oct;34(5):486-9. doi: 10.1097/AAP.0b013e3181ae11af.</citation>
    <PMID>19920424</PMID>
  </reference>
  <reference>
    <citation>Akkaya T, Ersan O, Ozkan D, Sahiner Y, Akin M, Gümüş H, Ateş Y. Saphenous nerve block is an effective regional technique for post-menisectomy pain. Knee Surg Sports Traumatol Arthrosc. 2008 Sep;16(9):855-8. doi: 10.1007/s00167-008-0572-4. Epub 2008 Jun 24.</citation>
    <PMID>18574578</PMID>
  </reference>
  <reference>
    <citation>Manickam B, Perlas A, Duggan E, Brull R, Chan VW, Ramlogan R. Feasibility and efficacy of ultrasound-guided block of the saphenous nerve in the adductor canal. Reg Anesth Pain Med. 2009 Nov-Dec;34(6):578-80.</citation>
    <PMID>19916251</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <results_first_submitted>February 25, 2014</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2017</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bilateral total knee replacement</keyword>
  <keyword>Femoral Nerve Block</keyword>
  <keyword>Saphenous Nerve Block</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was from the period of 4/16/12-9/4/13 at the Hospital for Special Surgery. Patients were identified on the day of surgery and randomized prior to the start of surgery.</recruitment_details>
      <pre_assignment_details>Patients were excluded prior to randomization if they had contraindications to spinal or epidural anesthesia, had chronic opioid use, pre-existing neuropathies in the limbs, allergies to pre-operative medications, contraindication to assigned nerve blocks, allergy to local anesthetic, American Society of Anesthesia 4-5, and non-English speaking.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Technique Right Leg, Control Technique Left Leg</title>
        </group>
        <group group_id="P2">
          <title>Study Technique Left Leg, Control Technique Right Leg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.41" spread="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Scale Pain Score</title>
        <description>The primary outcome is the postoperative pain in each leg within the first 24 hours postoperatively. VAS pain scores could range from 0 to 10. Higher values represent a worse outcome.</description>
        <time_frame>Up to postoperative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Technique: Saphenous Nerve Block</title>
            <description>Study Technique: One leg will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>Control Technique: Femoral Nerve Block</title>
            <description>Control Technique: The other leg will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale Pain Score</title>
          <description>The primary outcome is the postoperative pain in each leg within the first 24 hours postoperatively. VAS pain scores could range from 0 to 10. Higher values represent a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="2.42"/>
                    <measurement group_id="O2" value="2.47" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tracking Total Opioid Usage</title>
        <time_frame>Up to postoperative day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Tracking Total Opioid Usage</title>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.11" spread="114.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preoperative and Postoperative Thigh Muscle Strength in Both Legs</title>
        <description>This was measured with a dynamometer to gauge strength.</description>
        <time_frame>Up to postoperative day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Technique: Saphenous Nerve Block</title>
            <description>Study Technique: One leg will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>Control Technique: Femoral Nerve Block</title>
            <description>Control Technique: The other leg will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Preoperative and Postoperative Thigh Muscle Strength in Both Legs</title>
          <description>This was measured with a dynamometer to gauge strength.</description>
          <units>kilogram-force unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.06" spread="10.65"/>
                    <measurement group_id="O2" value="17.24" spread="14.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-8 h postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="3.55"/>
                    <measurement group_id="O2" value="2.45" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="3.68"/>
                    <measurement group_id="O2" value="5.08" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="2.62"/>
                    <measurement group_id="O2" value="3.76" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Nerve Blocks</title>
        <description>Rated on a 0-10 scale, with a higher score representing greater satisfaction.</description>
        <time_frame>Up to postoperative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Technique: Saphenous Nerve Block</title>
            <description>Study Technique: One leg will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>Control Technique: Femoral Nerve Block</title>
            <description>Control Technique: The other leg will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Nerve Blocks</title>
          <description>Rated on a 0-10 scale, with a higher score representing greater satisfaction.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="2.4"/>
                    <measurement group_id="O2" value="8.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Motor and Sensory Blockade</title>
        <time_frame>Up to postoperative day 2</time_frame>
        <population>The duration of motor and sensory blockade was not calculated and analyzed, because accurate data regarding block resolution time could not be acquired from patients.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Duration of Motor and Sensory Blockade</title>
          <population>The duration of motor and sensory blockade was not calculated and analyzed, because accurate data regarding block resolution time could not be acquired from patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rating the Success of the Nerve Blocks</title>
        <time_frame>Up to postoperative day 2</time_frame>
        <population>The success of nerve blocks was not collected or analyzed. Instead, muscle strength was collected (data are presented in another table).</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Rating the Success of the Nerve Blocks</title>
          <population>The success of nerve blocks was not collected or analyzed. Instead, muscle strength was collected (data are presented in another table).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Complications</title>
        <time_frame>Up to postoperative day 2</time_frame>
        <population>Analysis of postoperative complications was not performed because sufficient data could not be collected regarding the secondary outcome</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Complications</title>
          <population>Analysis of postoperative complications was not performed because sufficient data could not be collected regarding the secondary outcome</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study was monitored for adverse events over the course of 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Technique: Saphenous Nerve Block</title>
        </group>
        <group group_id="E2">
          <title>Control Technique: Femoral Nerve Block</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Epidural failure</sub_title>
                <description>Epidural pump for patient malfunctioned</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stavros G. Memtsoudis, MD, PhD</name_or_title>
      <organization>Hospital for Special Surgery</organization>
      <phone>212-606-1206</phone>
      <email>memtsoudiss@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

